IL17A and breast cancer: Because IL-17 and the IL17 receptor have been examined and licensed for use in patients with a variety of inflammatory disorders, including psoriasis, psoriatic arthritis, and ankylosing spondylitis, it will be interesting to examine their influence on BC.